11:44 AM EST, 11/13/2024 (MT Newswires) -- Johnson & Johnson ( JNJ ) filed Tuesday a lawsuit seeking to stop the US Health Resources and Services Administration's attempts to block the company's rebate model under the federal 340B drug pricing program.

In its complaint filed at the US District Court for the District of Columbia, the company also sought to stop the Department of Health and Human Services or HHS, HRSA, and their respective heads from taking any enforcement action related to implementing the rebate model.

"Johnson & Johnson ( JNJ ) is taking action to bring much needed transparency essential to helping the 340B program achieve its original intent to support prescription drug access for vulnerable patients," a company spokesperson told MT Newswires Wednesday.

The HRSA declined to comment to MT Newswires, while the HHS didn't immediately respond to a request for comment

Price: 152.42, Change: -0.22, Percent Change: -0.14